Every material Form 8-K Electra Therapeutics, Inc. has filed with the SEC since September 21, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Electra Therapeutics, Inc. closed its initial public offering on September 21, 2026, selling 23,333,334 shares of common stock at $15.00 per share, for approximately $350.0 million in gross proceeds before underwriting discounts and offering expenses. The company also filed an amended and restated certificate of incorporation and adopted amended and restated bylaws effective on the closing date.
IPO: 23,333,334 shares of common stock sold at $15.00 per share
Gross proceeds of approximately $350.0 million before underwriting discounts and estimated offering expenses
Restated certificate of incorporation filed with Delaware and restated bylaws adopted, both effective September 21, 2026
Full terms are described in the final prospectus filed September 18, 2026 under Rule 424(b)
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Electra Therapeutics, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →